Sentences with phrase «with ovarian tumors»

And although most tumors in horses occur as they get older, this is not the case with ovarian tumors as these commonly occur in horses 5 to 9 years of age.

It is not uncommon to find mammary tumors in bitches and queens with ovarian tumors.

Their results demonstrate that specific rhoptry and dense granule effector proteins that T. gondii secretes before and after host cell invasion, respectively, control the development of an effective host antitumor response, and increase the survival of mice with ovarian tumors.

Not exact matches

«Nonetheless, the proof of concept studies we have obtained thus far are extremely encouraging, and we are confident that with proper support and efforts we could translate our findings into experimental therapeutics for a variety of solid tumors that are driven by EphA2 overexpression, including breast, lung, prostate, pancreatic, and ovarian cancers,» said Pellecchia, who serves as the founding director of the Center for Molecular and Translational Medicine at UCR.

Seventy four percent of enrolled patients were diagnosed with ovarian cancer with tumors that had relapsed and metastasized in the peritoneum, the membrane that lines the abdominal cavity.

Shih, Wang and their colleagues tested fostamatinib's power to reduce tumor size in mice implanted with human ovarian cancer cells that were resistant to paclitaxel.

So he implanted various human tumors — including ovarian, breast, colon, liver, and brain — into mice and then injected the animals with antibodies that disable CD47.

The research shows that ONA reduces the progression of malignant ovarian cancer tumors by interfering with the pro-tumor function of myeloid cells.

In an earlier Penn Medicine study, 38 percent of all patients (and 46 percent of females with the condition) were found to have a tumor, most commonly it was an ovarian tumor.

«Personalized tumor vaccine shows promise in pilot trial: Vaccine against patients» own tumors triggers a broad response, and induced five - year remission in one patient with advanced ovarian cancer.»

«While the presence of lymphocytes in tumors is often associated with better clinical outcomes, this research adds clarity on the diversity of T cells within the tumor environment and their influence on ovarian cancer outcomes,» says first author Kunle Odunsi, MD, PhD, FRCOG, FACOG, Deputy Director, M. Steven Piver Professor and Chair of Gynecologic Oncology, and Executive Director of the Center for Immunotherapy at Roswell Park.

Importantly, elevated BRCA1 methylation was confined to patients diagnosed with so - called high - grade serous tumors, the most aggressive variant of ovarian cancer, which also is the variant associated with BRCA1 mutations.

Their ability to pinpoint tumors with submillimeter accuracy could eventually improve early detection and treatment of ovarian cancer.

«We found a striking difference between the metabolic profiles of poorly aggressive and highly aggressive ovarian tumor cells, particularly with respect to their production and use of the amino acid glutamine,» said lead researcher Deepak Nagrath of Rice.

This new approach to classifying ovarian tumors can help doctors make the right management decisions, which will improve the outcome for women with cancer.

A section of a tumor organoid grown from cells derived from a patient with high - grade serous ovarian cancer (left) and a mini-tumor treated with ReACp53, resulting in extensive cancer cell death.

But mutations, which are found in 96 percent of patients with high - grade serous ovarian tumors, can cause p53 to form clumps, or «aggregates,» which impair the protein's normal function.

Ten women underwent surgery based on their ultrasound exams, with four having invasive ovarian cancers, two having ovarian tumors of low malignant potential, one having endometrial cancer, and three having benign ovarian tumors.

She estimates that about 50 percent of women with ovarian cancer have tumors with this type of tumor and would qualify for the trial, which needs about $ 2 million in philanthropic funding before it could begin.

In their research, scientists at Rutgers created animal models that closely resemble the cancerous tumors found in women with ovarian cancer by injecting tumor tissues obtained from gynecological cancer patients treated at the Cancer Institute into laboratory mice.

The team collected tumors from 68 women affected with ovarian and uterine CSs to try to determine the molecular basis of the tumor's aggressive behavior.

They found that tumor cells with the mutant genes were particularly sensitive to a drug, olaparib, recently approved for the treatment of hereditary ovarian cancer.

VIC - 008 is a fusion protein combining an immune - activating protein from the tuberculosis bacteria with a small antibody fragment targeting mesothelin, a protein expressed in several types of tumor — including mesothelioma, pancreatic and ovarian cancer.

They found that the defect is highly sensitive to an existing FDA - approved drug used to treat ovarian cancer — a discovery that challenges current practice for treatment of brain tumors and other cancers with the same genetic defect, said the scientists.

Women with Stage III ovarian cancer given a combination of intravenous and intraperitoneal chemotherapy following surgical debulking of tumor had a median survival nearly 16 months longer than women who received IV chemotherapy alone, according to a study published conducted by the Gynecologic Oncology Group (GOG), a National Cancer Institute - supported research network, in the January 5, 2006 issue of the New England Journal of Medicine.

Next they treated the experimental tumor cells with MIR506 to determine if it would behave in the same way it had with ovarian and other cancers.

«I want to find those early - stage tumors, and I want to increase the survival of patients with ovarian cancer.»

The earliest and one of the most striking came from observations that the presence of infiltrating T cells (called «tumor - infiltrating lymphocytes,» or TILs) in ovarian tumors is positively and strongly associated with improved survival of patients with ovarian cancer [1].

Hammond has ongoing investigations with both of those labs, work that could lead to a theranostic nanoparticle that simultaneously identifies ovarian tumors and hits them hard.

Their theory was first confirmed with ovarian cancer cell lines and then the Peter / Lengyel team tested HGMA2 protein levels in tumor samples from 100 patients with ovarian cancer.

[2] Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K. Intraepithelial CD8 + tumor - infiltrating lymphocytes and a high CD8 + / regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

NK cells are a key part of the innate immune system with the ability to recognize and kill diverse types of tumor cells, including ovarian cancer.

This raises the exciting possibility that therapies for ovarian cancer might benefit patients with Basal breast tumors, and vice-versa.

Dr. Matsuzaki has accumulated extensive expertise in T - cell biology and mechanisms of immune suppression in periphery and tumor microenvironments in patients with ovarian cancer.

Over the past few years, they have extended their research to understand how products of cellular necrosis and the innate immune responses they induce affect the tumor microenvironment, with a specific focus on ovarian cancer.

Alexandra Snyder, MD, is a translational physician scientist at Memorial Sloan Kettering Cancer Center (MSKCC) who specializes in the study of tumor genetics and response to checkpoint blockade immunotherapy in solid tumors, with a particular focus on ovarian cancer.

The approach developed by the MGH team starts with the engineered protein, which in this case fuses an antibody fragment targeting a protein called mesothelin — expressed on the surface of such tumors as mesothelioma, ovarian cancer and pancreatic cancer — to a protein from the tuberculosis bacteria that stimulates the activity of dendritic and other immune cells.

«Visualizing how cancer cells interact with a tumor microenvironment that accurately reflects the complex biology of ovarian cancer should help us understand the mechanisms underlying metastatic progression as well as identify new therapeutics that can inhibit this process,» said clinical gynecologic oncologist Ernst Lengyel, MD, PhD, senior author of the study and a professor of obstetrics and gynecology at the University of Chicago.

Association and prognostic significance of BRCA1 / 2 - mutation status with neoantigen load, number of tumor - infiltrating lymphocytes and expression of PD - 1 / PD - L1 in high grade serous ovarian cancer.

Poznansky adds that the tumors that might be treated with the mesothelin - targeting vaccine — ovarian cancer, pancreatic cancer and mesothelioma — all have poor survival rates.

Almost 10 years after Kathy Bates was diagnosed with ovarian cancer, her doctors found a tumor in her left breast.

The chronically stressed mice had decreased immune function and experienced tumor development significantly earlier than the non-stressed mice.16 Other mouse studies of ovarian cancer showed that chronic stress resulted in increased cancer growth as well as increased angiogenesis, the process with which cancer forms new blood vessels to feed itself nutrients for growth and metastases.17 Chronic stress has also been shown to decrease our body's ability to mount an attack against foreign invaders, including viruses.18 As we know that several viruses can cause cancer (HPV and cervical cancer, and EBV and nasopharyngeal cancer), we can extrapolate that any decrease in immune function could increase cancer risk.

MD Anderson cancer center uses about 4 tablespoons of flax seeds daily to significantly lower testosterone in their patients with androgen secreting ovarian tumors.

Although this tumor was thankfully benign, it's important to familiarize yourself with the symptoms of ovarian cancer — especially since most signs of the illness aren't as obvious as a large, fast - growing mass.

In the situation of this type of tumor, signs of heat are constant; they do not cycle as with ovarian tissue.

Reproductive disorders such as pyometra, mammary tumors, testicular cancer, ovarian cancer, and prostate cancer are also reduced / prevented with neutering (reviewed in [2]-RRB- although neutering has been associated with increased risk or aggressiveness of prostatic cancer [3 — 5].

Along with birth control, behavioral correction, and removal of sexual frustration, various kinds of reproductive tract problems such as ovarian and uterine tumors, mammary gland tumors and cervical tumors can be prevented with feline spaying.

However, this is not absolute and an ovarian epithelial tumor has been recorded in association with pyometra (pus in the uterus) at one year of age.

There is evidence that she will benefit by having the ovaries and uterus removed because it can reduce her chances of masking her tumors with a false pregnancy and eliminates the risk of ovarian and uterine tumors.

In just the past two months a friend lost her sister to ovarian cancer; another friend was diagnosed with prostate cancer; a high school friend died of throat cancer; a friend in her 20s had a recurrence of the rare brain tumor that... Continue Reading